Back to today’s briefing

Story perspectives

Roche's New Antibiotic Enters Trials Against Superbug Threat

5/28/2025

25 3

Summary

Story summary

Roche is taking a bold step in the fight against antibiotic resistance with its new antibiotic, zosurabalpin, now entering phase-three trials. Developed alongside Harvard researchers, this innovative drug targets the notorious superbug Acinetobacter baumannii. With 400 patients set to participate, the trial is anticipated to kick off later this year or early 2026, offering hope in a critical battle for global health.

1 of 1

Story summary

Roche is taking a bold step in the fight against antibiotic resistance with its new antibiotic, zosurabalpin, now entering phase-three trials. Developed alongside Harvard researchers, this innovative drug targets the notorious superbug Acinetobacter baumannii. With 400 patients set to participate, the trial is anticipated to kick off later this year or early 2026, offering hope in a critical battle for global health.